麴菌症治療市場：依藥物類別、疾病和地區分類

據估計，麴菌症治療市場在 2026 年將達到 42 億美元，預計到 2033 年將達到 59 億美元。預計從 2026 年到 2033 年，該市場將以 5.0% 的複合年成長率成長。

麴菌症是由曲霉菌感染引起的一組疾病。曲霉菌是一種真菌，其孢子存在於空氣中，但通常不會引起疾病。肺部疾病患者、免疫系統較弱者或過敏體質者更容易感染曲霉菌。常見的麴菌感染疾病包括侵襲性麴菌症、非侵襲性過敏性肺麴菌症（ABPA）和慢性肺部麴菌球（CPA）。唑類藥物是唯一具有抗麴菌活性的口服藥物，Itraconazole和Voriconazole被認為是治療慢性肺部麴菌症的第一線藥物。

市場動態

該市場的主要企業正致力於研發和獲得治療慢性麴菌症的新療法的批准，預計這將為市場參與企業提供推出創新麴菌症治療產品的機會。例如，2017年10月，邁蘭公司（Mylan NV）推出了醋酸卡泊芬Caspofungin注射液，這是默克公司（Merck & Co.）Cancidas的首批學名藥之一。此藥適用於對其他療法有抗藥性或不耐受的侵襲性麴菌症病患者。此外，該市場的主要企業正專注於諸如獲得美國食品藥物管理局（FDA）批准等成長策略，預計這將推動預測期內的市場成長。例如，2020年1月，PULMATRiX公司宣布，美國食品藥物管理局（FDA）已授予其PUR1900（Plumazole）簡審類。該公司正在開發吸入式Itraconazole抗真菌藥物候選物，用於治療氣喘患者的過敏性支氣管麴菌症（ABPA）。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數介紹了全球慢性麴菌症治療市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份《全球慢性麴菌症治療市場》報告的目標對象包括業界的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用分析全球慢性麴菌症治療市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 產品核准
• 合作關係、併購
• 監理情勢
• PEST分析
• 波特五力分析
• 流行病學
• 穩健的管道分析

第4章 全球麴菌症治療藥物市場：依藥物類別分類，2021-2033年

• 皮質類固醇
• 抗真菌藥物

第5章 全球麴菌症治療市場：依疾病類型分類，2021-2033年

• 慢性肺麴菌症
• 過敏性支氣管麴菌症
• 過敏性麴菌病鼻竇炎
• 麴菌球
• 皮膚麴菌症

第6章 全球麴菌症治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• 熱圖分析
• 市佔率分析
• 公司簡介
  • Abbott Laboratories
  • AstraZeneca plc Company Highlights
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Johnson & Johnson Services, Inc.
  • Mylan Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Ltd.
• 分析師意見

第8章

• 參考
• 調查方法
• 關於本公司

Aspergillosis Treatment Market is estimated to be valued at USD 4.2 Bn in 2026 and is expected to reach USD 5.9 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.0% from 2026 to 2033.

Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to aspergillus induced infection. Common aspergillus infections include invasive aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary Aspergilloma (CPA). Azoles are the only oral drug with anti-aspergillus activity and itraconazole and voriconazole are considered as first-line drugs for chronic pulmonary aspergillosis.

Market Dynamics

Key players operating in the market are focusing on development and approval of novel therapeutics for the treatment of chronic aspergillosis, which is expected to offer a lucrative opportunity to the market players to launch innovative products in the market for the treatment of aspergillosis. For instance, In October 2017, Mylan N.V. launched caspofungin acetate for injection, one of the first generic versions of the U.S. pharma giant Merck's & Co's Cancidas. It is indicated for invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Furthermore, key companies in the market focusing on growth strategies such as FDA approvals which is expected to drive the growth of the market over forecast period. For instance, In January 2020, PULMATRiX, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to PUR1900 (Pulmazole). The company's inhaled itraconazole antifungal candidate is developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Key features of the study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic aspergillosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chronic aspergillosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic aspergillosis treatment market

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
• Corticosteroids
• Anti-fungal
• By Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
• Invasive Aspergillosis
• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis
• Allergic Aspergillus Sinusitis
• Aspergilloma
• Cutaneous Aspergillosis
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players
• Abbott Laboratories
• AstraZeneca plc
• Eli Lilly and Company
• GlaxoSmithKline
• Johnson & Johnson Services, Inc.
• Mylan Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• TRakeda Pharmaceutical Company Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Aspergillosis Treatment Market, By Drug Class, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Anti-fungal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Aspergillosis Treatment Market, By Disease Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Chronic Pulmonary Aspergillosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Allergic Bronchopulmonary Aspergillosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Allergic Aspergillus Sinusitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Aspergilloma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Cutaneous Aspergillosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Aspergillosis Treatment Market, By Region, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AstraZeneca plc Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • GlaxoSmithKline
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Johnson & Johnson Services, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Mylan Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Takeda Pharmaceutical Company Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us